Annual Report Overview 2018
Download PDF

Innovating
antibodies,
improving
lives

Annual Report Overview 2018

Genmab In Short

Genmab is an international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.

2 Marketed Products

DARZALEX® marketed in the U.S., Europe, Japan & other countries; Arzerra® marketed in the U.S. and Japan

4 Proprietary Antibody Products in Clinical Development

Tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5 & DuoBody-CD3xCD20

4 Proprietary Technologies

DuoBody® bispecfic platform, HexaBody® platform, DuoHexaBody™ platform & HexElect™ platform

2 Categories of Cancer

Generate products to treat solid tumors & hematological cancers

~20 Pre-clinical Projects

Extensive partnered & own pre-clinical pipeline

31 INDs

Investigational new drug applications filed by Genmab and partners since 1999

Shareholder letter

In 2018, we continued to build Genmab’s robust innovative pipeline, advancing our four proprietary programs, announcing our new proprietary HexElect antibody technology and entering a new strategic collaboration.

– Jan van de Winkel, Ph.D. President & CEO

Financial Highlights

Revenue
Operating Expenses
Operating Result
MDKK
2014
2015
2016
2017
2018

Our Vision

By 2025, our own product has transformed cancer treatment, and we have a pipeline of knock-your-socks-off antibodies.

Our Three-pronged Strategy

    2019 outlook & objectives

    Our goals and financial outlook for 2019 are designed to advance Genmab towards our 2025 vision.

    Investor Relations Contact:
    Rachel Curtis Gravesen
    Senior Vice President
    Investor Relations & Communications
    T: +45 33 44 77 20
    E: rcg@genmab.com
    © 2019 Genmab A/S